Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ATEN -17.8% (provides guidance for Q3/Q4), CALM -11.4%, HELE -5%
Other news:
- CDNA -4.8% (Supreme Court denies CDNA request for appeal in patent case with Natera; issues statement on Supreme Court decision regarding Stanford-Licensed Patents)
- NVS -4% (executes Sandoz Spin-off; reaffirms outlook)
- TRN -3.6% (reports Q3 railcar deliveries below projections due closing of the US-Mexico border)
- KRTX -3% (to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress)
- MLTX -2% (Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress)
- TAK -1.8% (dengue vaccine recommended by WHO advisory group)
- BP -1.6% (exploring possible sale of 49% stake in US pipeline network according to Reuters)
- OCUL -1.3% (initiates first pivotal clinical trial of OTX-TKI in Wet AMD)
- PODD -1.1% (CFO to step down)
Analyst comments:
- TSE -2.3% (downgraded to Hold from Buy at Jefferies)
- ON -1.6% (downgraded to Neutral from Outperform at Exane BNP Paribas)
- R -1.3% (downgraded to Peer Perform from Outperform at Wolfe Research)
- AAPL -1% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)